IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Consensus Rating of “Buy” by Brokerages

Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) have received an average recommendation of “Buy” from the thirteen ratings firms that are currently covering the firm, Marketbeat.com reports. Thirteen research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokerages that have covered the stock in the last year is $48.27.

A number of research analysts have issued reports on the company. Citigroup boosted their price target on IDEAYA Biosciences from $40.00 to $60.00 and gave the company a “buy” rating in a report on Thursday, March 21st. The Goldman Sachs Group decreased their price target on IDEAYA Biosciences from $53.00 to $46.00 and set a “buy” rating for the company in a report on Monday, May 13th. Wedbush reissued an “outperform” rating and issued a $52.00 price target on shares of IDEAYA Biosciences in a report on Wednesday, May 8th. Stifel Nicolaus boosted their price objective on IDEAYA Biosciences from $55.00 to $63.00 and gave the company a “buy” rating in a research report on Tuesday, June 4th. Finally, BTIG Research began coverage on IDEAYA Biosciences in a research report on Friday, March 8th. They issued a “buy” rating and a $55.00 price objective for the company.

Insider Buying and Selling

In related news, insider Michael Anthony White sold 28,500 shares of the business’s stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $36.24, for a total transaction of $1,032,840.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, insider Michael Anthony White sold 28,500 shares of the business’s stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $36.24, for a total transaction of $1,032,840.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Yujiro S. Hata sold 34,433 shares of the company’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $41.81, for a total value of $1,439,643.73. Following the completion of the sale, the chief executive officer now owns 677,887 shares of the company’s stock, valued at $28,342,455.47. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 119,644 shares of company stock worth $4,832,228. 3.50% of the stock is owned by corporate insiders.

Institutional Trading of IDEAYA Biosciences

Several large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its holdings in IDEAYA Biosciences by 19.6% in the 1st quarter. Vanguard Group Inc. now owns 4,155,757 shares of the company’s stock valued at $182,355,000 after buying an additional 679,985 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in IDEAYA Biosciences by 13.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,052,500 shares of the company’s stock valued at $177,825,000 after buying an additional 486,222 shares in the last quarter. Federated Hermes Inc. grew its holdings in IDEAYA Biosciences by 14.8% in the 4th quarter. Federated Hermes Inc. now owns 3,883,775 shares of the company’s stock valued at $138,185,000 after buying an additional 500,046 shares in the last quarter. Janus Henderson Group PLC grew its holdings in IDEAYA Biosciences by 7.2% in the 1st quarter. Janus Henderson Group PLC now owns 3,808,450 shares of the company’s stock valued at $167,104,000 after buying an additional 256,559 shares in the last quarter. Finally, Capital Research Global Investors lifted its stake in shares of IDEAYA Biosciences by 43.6% in the 4th quarter. Capital Research Global Investors now owns 1,976,870 shares of the company’s stock valued at $70,337,000 after purchasing an additional 600,000 shares during the last quarter. 98.29% of the stock is currently owned by hedge funds and other institutional investors.

IDEAYA Biosciences Trading Up 2.2 %

Shares of IDEAYA Biosciences stock opened at $35.11 on Monday. The firm has a market cap of $2.66 billion, a P/E ratio of -17.47 and a beta of 0.79. IDEAYA Biosciences has a 12 month low of $20.90 and a 12 month high of $47.74. The stock’s fifty day moving average price is $39.00 and its 200-day moving average price is $40.68.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings results on Tuesday, May 7th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.02). IDEAYA Biosciences had a negative net margin of 483.05% and a negative return on equity of 20.09%. The firm’s revenue for the quarter was down 100.0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.49) EPS. Analysts forecast that IDEAYA Biosciences will post -2.37 earnings per share for the current year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.